# Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Study · id `cardio:ct-nct02376010` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02376010](<https://clinicaltrials.gov/study/NCT02376010>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02376010

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT02376010. Randomized; no masking; primary purpose prevention. Start 2015-04-02 (actual); primary completion 2018-04-01 (actual). Results posted on 2021-07-22.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT02376010, source copy `cardio:ctgov-nct02376010-2024-10-15`, retrieved 2026-10-26)
- Started: 2015-04-02 (actual) (ClinicalTrials.gov record NCT02376010, source copy `cardio:ctgov-nct02376010-2024-10-15`, retrieved 2026-10-26)
- Primary completion: 2018-04-01 (actual) (ClinicalTrials.gov record NCT02376010, source copy `cardio:ctgov-nct02376010-2024-10-15`, retrieved 2026-10-26)
- Completion: 2018-04-01 (actual) (ClinicalTrials.gov record NCT02376010, source copy `cardio:ctgov-nct02376010-2024-10-15`, retrieved 2026-10-26)
- Results first posted: 2021-07-22 (ClinicalTrials.gov record NCT02376010, source copy `cardio:ctgov-nct02376010-2024-10-15`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02376010, source copy `cardio:ctgov-nct02376010-2024-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02376010-2024-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
- Condition: Atherosclerosis
- Intervention (Drug): rivaroxaban
- Intervention (Drug): Warfarin
- Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (`cardio:org-lundquist-institute-for-biomedical-innovation-at-harbor-439991`)

## Provenance

Content hash: d9ad9a4829e2e27f1b7764d3001808ac4979f32eeb4e5a213d3b6c5eb981a819
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
